1 Francesca Laylah Jamilah 108 iryou/iryou/topics/tp html Fran
|
|
|
- しまな えいさか
- 7 years ago
- Views:
Transcription
1 108 Francesca Laylah Jamilah A B C D E F G H I A B C D E F G H I
2 1 Francesca Laylah Jamilah iryou/iryou/topics/tp html Francesca Laylah Jamilah 2 fibre 2
3 3 3.1 A 1. (a., b. ) (a., b., c. ) 1) 2. Kaposi ( ) ( ) 2) Steavens-Johnson 3. 3) (a., b. ) (a., b. ) 4. 4) ( ) 5) (a. B, b. T ) % 6) (a., b. ) (a., b. ) 5. ( ) 7) 0 0-I 0-III 0-I 0-III 0-I ( ) ( ) (a., b., c. ) 0-III ( ) 0-II 0-II 0-IIa 0-IIc 0-IIa 0-I ( ) 0-IIc 0-III ( ) 0-IIb 0-II 8) 6. Candida albicans Candida (a., b., c. ),, 1) (a., b., c. ) 9) ( ) 9) 3
4 ( ) ( ) 1) 9) ( 108 ) 7. ( ) ( ) Cushing ( ) 7) Cushing ( ) (a., b. ) (a., b. ) (a., b. ) (a., b. ) ( ) Na +, Cl 7) ( ) 10) 8. (a., b., c. ) ( ) (a., b., c. ) 20 11) ( ) ( ) 9. ( ) ( ) ( ) (a., b., c. ) 10. ( ) ( ) (a., b. ) (a., b. ) (a., b. ) (a., b. ) 11. ( ) ( ) ( ) ( ) ( ) 12. (a., b. ) 3 (a., b. ) Stanford ( ) A ( ) B De Bakey I (a., b. ) (a., b. ) II ( ) III ( ) 8) 4
5 13. (a., b. ) T2 ( ) ( ) ( ) ( ) 9) ( ) ( ) ( ) ( ) (a., b. ) ( 108 ) 14. ( ) (a., b., c. ) 13) ( ) (a., b. ) 15. (a., b., c. ) (a., b., c. ) 16. ( ) ( ) ( ) 5) (a., b., c. ) (a., b. ) (a., b. ) 5) (a., b. ) (a., b. ) 6) 17. ( ) ( ) 5) (a., b., c. ), (a., b., c. ), (a., b., c., d. ), (a., b., c. ) (a., b. ) 30 (a., b. ) 14) ( ) (a., b. ) 7) ( ) (a., b. ) 7) ( ) (a., b. ) (a., b. ) (a., b. ) (a., b. ) (a., b. 5
6 ) 5) (a., b. ) 18. (Graft-versus-host disease; GVHD) ( ) GVHD GVHD GVHD (a., b., c. ) GVHD ( ) ( ), ( ), ( ) GVHD ( ) (a., b. ) GVHD (a., b., c. ) ( ) 2) 19. ( ) ( ) (a., b., c. ) ( ) ( ) ( ) 1-3 % ( ) 10 % ( ) -O- ( ) ( ) 10) 20. ( ) (a., b. ) (a., b. ) ( ) Na + (a., b. ) (a., b. ) 14) Sheehan ( ) ( ) ( ) (a., b. ) 21. ( ) (a., b., c. ) 1 (a., b., c. ) ( ) (a., b. ) ( ) (a., b. ) (a., b. ) (a., b., c. ) (a., b. ) 6
7 (a., b. ) ( ) 15) 22. ( ) ( ) ( ) ( ) ( ) (a., b., c. ) ( ) ( ) ( ) 16) 23. ( ) ( ) ( ), ( ) ( 108 MR ) 24. ( ) I ( ) (a., b. ) 11) ( 108 ) 25. ( ) ( ) ( ) (a., b. ) ( ) ( ) ( ) ( ) 12) D-dimer (a., b. ) 26. (a., b. ) (a., b., c. ) ( ) ( ) ( ) ( 108 ) FISH (a., b. 7
8 ) ( 108 BCR/ABL 1 ) 30. α ( ) ( ), ( ) ( ) ( ) (a., b. ) (a., b. ) 31. ( ) ( ) Wilson (a., b. ) (a., b. ) Leigh ( ) ( ) (a., b. ) ( ) Gaucher ( ) (a., b. ) (a., b. ) Machado-Joseph (a., b., c., d. ) MJD CAG ( ) 7) Duchenne Becker ( ) ( ) (a. Duchenne, b. Becker) (a. Duchenne, b. Becker) 32. ( ) ( 108 ) CT MRI (a., b. ) ( ) ( ) ( ), ( ) ( 108 ) 35., ( ), ( ) ( ) (a., b., c. ) (a., b., c. ) (a., b. ) (a., b. ) 17) (a., b. ) 8
9 PCR PCR (a., b., c. ) (a., b. ), (a., b. ) ( ) (a., b. ) (a., b. ) (a., b. ) (a., b. ) (a., b., c. ) PET/CT (a., b., c. ) (a., b. ) 38. ( ) 16) ( ) (a., b., c., d. ) (a., b. ) (a. CT, b. MRI, c. SPECT, d. PET/CT) 18) ( ) (a., b. ) (a., b., c. ) ( ) ( ) 19) ( ) (a., b., c., d. β, e. ) ( ) (a., b., c., d., e. ) (a., b., c., d., e. ) ( ) (a. β, b. β, c. α, d. α ) ( ) ( ) 5) ( ) (a., b. ) ( ) 20) ( ) 45. 9
10 (a., b. ) ( ) (a., b. ) CT MRI (a., b. ) (a., b., c. ) 15) (a., b. ) ( ) ( ) (a., b. ) ( ) (a., b. ) (a., b., c. ) Jo-1 ( ) ( ) % DNA (a., b. Sjögren, c., d. SLE, e. ) ( ) ( ) (a., b., c. ) (a., b. ) (a., b. Sjögren, c., d. SLE, e. ) I ( ) ( ) 51. ( ) Staphylococcus Streptococcus (a., b. ) β (a., b., c. ) ( ) ( ) 52. ( ) ( ), ( ),, ( ) ( ) ( ) ( ) ( ) (a., b. ) (a., b. ) 10
11 ( ) (a., b. ) ( ) (a., b. ) (a., b. ) ( ) ( ) TGF-β ( ) ( ) (a., b., c. ) (a., b. ) ( ) 8) ( ) (a., b., c. ) ( ) ( ) 55. (a., b. ) B B ( ) ( ) ( ) ( ) ( ) ( ) 1 2 ( ) ( ) ( ) (a., b. ) 45 (a., b. ) ( ) (a., b. ) ( ) ( ) 21) (a., b. ) ( ) LDH ( ) ( ) (a., b. ) 56. ( ) (a., b. ) ( ) 57. ( ) ( ) (a., b. ) ( ) 11
12 58. HTLV-1 ( ) HTLV-1 (a. B, b. T ) (a. CD4, b. CD8, c. CD20) (a., b. ) HTLV-1 (a., b. ) HTLV-1 RANK (a. K, b. K, c. Ca, d. Ca ) ( ) 22) 59. ( )
13 3.2 B ( ) ( ) 2. ( ) (a., b. ) (a., b., c. ) (a., b. ) (a %, b %, c. 0.5 %, d. 1 %) (a., b. ) (a., b., c. ) (a., b., c. ) (a., b. ) ( ) Hz (a. α, b. β, c. γ, d. δ, e. λ, f. θ) (a., b. ) (a., b. ) (a., b. ) REM ( ) (a., b. ) (a., b. ) 11. ( ) (a., b., c. ) 10 ( ) 7)
14 (a., b. ) (a., b. ) (a., b. ) 13. AIDS AIDS ( ) ( ) ( ) ( ) ( ) ( ) ( ) AIDS 5) ( ) AIDS PIVKA-II ( ) ( ) ( ) ( ) ( ) (a., b., c., d. ) (a., b., c., d. ) (a. A, b. B, c. C, d. D, e. E., f. K) ( ) PIVKA-II (a., b. ) ( ) PIVKA-II (a., b. ) ( ) ( ) 4) 22. ( ) ( ) ( ) 1 (a., b., c., d., e., f. ) ( ) ( ) 2 (a., b., c., d., e., f. ) ( ) ( ) 3 (a., b., c., d., e., f. ) ( ) ( ) 9) ( ) 4) (a. 1, b. 2, c. 3, d. ) 14
15 23. ( ) HE (a., b. ) (a., b. ) (a., b. ) ( ) (a., b., c., d. ) (a., b., c., d. ) (a., b., c., d., e. ) ( ) ( ), ( ) 26. (a., b. ) (a., b., c. ) ( ) ( ) (a., b., c. ) (a., b., c., d. ) (a., b., c. ) ( ) ( ) (a., b. ) ( ) (a., b. ) ( ) (a., b. ) 2)
16 (a., b., c. ) (a., b., c., d. ) (a., b. ) (a., ) (a., b. ) 6) (a., b. ) (a., b., c., d. ) ( ) 23) 36. (a., b. ) 20) (a., b. ) (a., b. ) (a., b., c. ) Na + -K + ATPase (a., b., c. ) Na + (a., b. ) (a., b. ) ( ) Na + (a., b., c. ) (a., b. ) (a., b. ) ( ) (a., b. ) (a., b. ) (a., b. ) ( ) ( ) (a., b. ) ( ) (a., b. ) ( ) ( ) ( ) ( ) 24) ( ) ( ) ( ) ( ) ( ) 42. ( ) ( ) body mass index (BMI) 16
17 BMI ( ) ( ) BMI (a., b., c., d. ) BMI BMI ( ) 7) Nelson Textbook of Pediatrics 25) 3 BMI ( ) (97 ) (a. 2, b. 6, c. 10) BMI 20) (a., b., c. ) (a., b. ) (a., b., c. ) ( 108 ) 45. postpartum depression (a., b. ) (a., b. ) (a., b. ) ( 108 ) (a., b., c. ) (Systemic Lupus Erythemathosus; SLE) 70 % ( ) ( ) ( ) 2) (a. I, b. II, c. III, d. IV ) SLE SLE (a., b. ) ( 108 SLE ( ) SLE ) 49. ( ) (a , b , c ) (a , b , c ) 26) (a., b., c. 17
18 ), ( ) ( ) (a., b. ) ( ) ( ) ( ) ( ) (a., b., c. ) ( ) ( ), ( ),, ( ) ( ) ( ) 26) HMG-CoA ( ) 10) ( 108 B-54 ) ( ) ( ) (a., b. ) (a., b. ) B 1 ( ) ( ) 8) B 1 ( ) ( ) B ( ), ( ), ( ) ( ) 7) ( ) 7) ( ) ( ) ( ) (a., b. ) 60. (Motor nerve Conduction Velocity; MCV) ( ) (Compound Muscle Action Potential; CMAP) (a. E, b. F, c. N, d. M) ( ) latency ( ) ( ) ( ) ( ) ( ) ( ) CMAP ms ( ) (a., b., c., d. ) CMAP (a., b., c. ) (a., b., c. ) (a., b. ) 18
19 (a., b. ) F ( ) 27) ( 108 ) 61. Guillain Barré ( ) (a., b., c. ) 17) ( ) ( ) ( )
20 3.3 C ( ) 6 (a., b., c. ) (a., b., c. ) ( ) ( ), ( ), ( ) 3 8) 5. (a., b., c. ) (a., b., c. ) ( ) 14) (a., b. ) (a., b., c. ) (a., b., c. ) ( ) (a., b., c. ) 23) 8. ROC 28) (a., b., c. ROC ) ( 108 ) 9. ( ) ( ) (a., b., c. ) 10. ( ) ( ) ( ) 26) ( 108 ) 11. ( ) ( ), ( ) 20
21 ( ) ( ) 17) (a., b., c. ) (a., b. ) ( 108 ) ( 108 ) ( 108 )
22
23 3.4 D ( ) (a., b. ) (a. 800, b. 80, c. 8) (a., b. ) (a., b. ) ( ) ( ) 13) ( ) (a , b , c ) mmhg 7) 5. ( ) ( ) ( ) (a. S1, b. S4) (a., b. ) S1 S4 (a. S1, b. S4) 4) 6. seizure generalised seizure ( ) focal seizure ( ) ( ) primary generalised seizure ( ) secondary generalised seizure ( ) ( ) (a., b., c. ) (a., b., c., d., e. ) (a., b. ) (a., b., c. L, d. T ) ( ) ( ) Na + ( ) (a., b. ) Na + T (a., b. GABA, c. ) (a., b. ) ( ) ( ) ( ) 10) 7. Wiskott-Aldrich (a., b. X, c. Y ) WAS deletion (a., b., c. ) ( ), ( ) WAS ( ) 25) ( 108 ) 8. Creutzfeldt-Jakob (CJD) ( ) ( ) ( ) 134 C 1 23
24 (SDS) 1) SDS (a. Polymerase Chain Reaction (PCR), b., c. ) 29) ( ) ( ) (a., b., c. ) ( ) ( ) ( ) (a., b. ) 5) syndrome ( ) sequence ( ) ( ) Potter sequence ( ) (a., b. ) ( ) 5, 25) Potter sequence (a., b. ) ( ) 16. ( ) ( ) 22) (a., b., c. ) ( ), ( ), ( ) (International Prognostic Scoring System; IPSS) 22) IPSS (a., b., c. ) ( 108 ) 17. (a., b. ) (a., b. ACTH, c. ) ( ) 24
25 (a., b. ) ( ) 11-α ( ) Paragonimus westermanii,,, (a., b., c. ) (a., b. ) 30) ( 108 ) 22. (Computed Tomography; CT) (a., b. ) ( 108 ) 23. ( 108 ) 24. ( 108 ) 25. ( ) ( 108 ) Blumberg ( ) ( ) ( ) 7) 25
26 (a., b. ) (a., b. ) (a., b. ) 15) (a., b. ) ( 108 ) 28. ( ) (a., b., c., d. ) (a., b. ) (a., b. ) ( ) 8) 29. (a., b., c. ) (a., b., c. ) ( ) (a., b. ) ( ) 9) ( ) 7) ( 108 ) 30. Huntington 4p16.3 ( ) CAG (a., b., c. ) ( ) ( ) ( ) CAG (a., b., c. ) ( ) (a., b. ) (a., b. ) Charcot-Marie-Tooth (a., b., c. X, d. ) ( ) ( ) (a., b. ) (a., b , c. ) Duchenne Becker (a., b., c. ) Genomics ( ) ( ) (a. 1, b. 15, c. 30, d. 45) (a. Duchenne, b. Becker ) 16 ( ) 17) 31. (a., b., c., d. ) ( ) ( ) (a. 5-10, b , c ) % ( ) (a., b. ) ( ) (a., b. ) 31)
27 34. ( ) ( ) ( ) ( ),, ( ) ( ) ( ) ( ) 2) ( ) ( ) ( 108 ) 37. (Toxic Epidermal Necrolysis; TEN) ( ) ( ) ( ) TEN ( ) (a., b., c., d. ) ( ) (a., b., c. ) (a., b., b. T ) 2) ( ) ( ) (a., b., c. ) 15) 2) ( 108 (Staphylococcal Scalded Skin Syndrome; SSSS) a. b. ) 38. ( ) ( ) 13) ( 108 ) 27
28 44. (a., b., c., d. ) ( ) 4) ( 108 ) 45. ( ) ( ) ( ) (a., b., c. ) 17) ( 108 CRP MRI ) ( 108 ) ( 108 ) 50. ( 108 ) ( 108 ) ( 108 ) 28
29 58. KL-6 ( ) (a., b., c. ) (a., b. ) (a., b. ) ( ) ( ) ( ) ( ) KL ) ( 108 ) ( ) ( ) CCP 32) 59. ( 108 )
30 3.5 E ( ) 24 ( ) (a., b., c. ) 7) 3. (a., b., c., d. ) (a., b., c. ) (a., b. ) 7) (a., b., c., d. ) (a., b., c., d. ) ( ) (a., b., c. 17-, d. ) ( ) 20) HE (Bowman ) (Descemet ) 33) 34) (a., b., c., d. ) (a., b., c., d. ) (a., b. I, c. II ) (a., b. ) (a. I, b. II, c. III, d. IV ) ( ) (a., b. I, c. II ) ( ) (a., b. ) (a., b., c. ) 33) (a., b., c., d. ) (a., b. ) 34) 13) 33) (
31 ) (a., b. ) (a., b., c. ) (a., b., c. ) 25) (a., b., c., d. ) (a. 1-2 %, b %, c %) 20) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) 2) ( ) 14. (a., b. ) (a., b. 3-8, c. 9 ) (a., b. 3-8, c. 9 ) (a. 8-15, b , c. 26 ) (International Commission on Radiological Protection; ICRP) 100 msv 35) (a., b. 1 msv, c. 10 msv, d. 50 msv ) 15. (a., b., c. ) 36) ( 108 )
32 20. ( ) 2001 ( ), ( ), ( ) 3 36) (a., b. ) (a., b. ) (a., b. ) 15) Rome III 3 1) (a., b. ); 2) (a., b. ); 3) (a., b. ) 8) Virchow (a., b. ) ( ) ( ) May R Thurner J 22 % 37) - 7) ( 108 ) ( 108 ) (a., b. ) (a., b. ) Retinitis Pigmentosa Retinopathia Pigmentosa (a., b. ) ( ) (a., b. ) (a., b. ) 13) ( ) ( ) ( ) 38) (Electroretinogram; ERG) ( ) ( ) ( ) ( ) 13) 32
33 ( ) ( ) ( ) (a. damp, b. dtmp, c. dgmp, dcmp) ( ) (a., b., c. ) RNA (a., c., b. ) MCV ( ) ( ) 22) (a., b., c. ) ( ) WHO (a., b. ) (a. 3, b., c., d. ) ( ) (a., b., c. ) ( ) WHO ( ) 36. ( 108 c ) 37. (a., b., c. ) ( ) ( ) (a,, b. ) (a., b. ) ( ) (a., b. ) (a., b., c. ) (a., b., c. ) (a., b. ) (a., b., c., d. ) 14) 33
34 ( ) 40. (a., b., c. ) 4 ( ) 41. ( ) (a., b. ) 42. (a., b. ) (a., b. ) (a., b. ) (a., b., c., d. ) µg/dl ( ) µg/dl δ- (a., b., c. ) 39) ( ) G6PD G6PD 40) (a., b., c. ) 39) ( 108 ) 43. ( ) ( ) ( ) (a., b. ) (a., b g, c. ) ( ) ( ) ( ) ( ) ( ) ( ) (a. 5, b. 15, c. 30, d. 45) (a. 5, b. 15, c. 30, d. 45) ( ) (a., b., c. ) ( ) 9) 44. ( 108 ) 45. TNM 34
35 (a., b. TNM ) IV ( ) III ( ) 41) 46. ( 108 ) 47. ( 108 ) ( 108 ) ( 108 ) ( ) ( ) ( ) ( ) (a., b., c. ) 55. ( ) (AChE) ( ) (a., b., c. ) VX AChE P=O AChE ( ) AChE P=O ( ) (a., b., c. ) (a., b. ) (a., b. ) AChE ( ) ( ) AChE ( ) (a., b., c. ) ( ) ( ) AChE 39) 35
36 56. ( ) ( ) (a., b. ) 9) ( 108 CT ) I ( ) II ( ) ( ) III II (a. I, b. II, c. III ) 9 (a., b., c. ) I (Burn Index; BI) II ( ) III 42) ( 108 )
37 3.6 F ( 108 ) 5. ( 108 ) (a., b. ) (a., b. ) ( ) ( ) ( ) ( ) (a., b. ) 2) (a., b. ) (a., b. ) (a., b. ) (a., b. ) ( ) ( 108 ) 10. ( 108 )
38 ( ) ( ) ( ) ( ) ( ) 16) : a., b., c., d., e ( 108 ) Glasgow Coma Scale (GCS) E ( ) V ( ) M ( ) = 15 3 E ( ) V ( ) M ( ) 12) 21. ( 108 ) 22. ( ) (a., b., c. c. ) 13) ( 108 FAST ) (a. 10, b. 20, c. 30, d. 40) mm ( ) ( ) (a. α, b. β, c. α, d. β ) ( ) (a., b., c. ) NSAID ( ) 9)
39 ( 108 ) ( 108 F-27 c ) ( 108 Buerger ) ( 108 ) 39
40 3.7 G ( 17( )202) (a., b. ) (a., b. ) 43) ( 108 ) (a., b., c., d. ) ( ) (a., b., c. ) ( ) (a., b. ) (a., b., c. ) ( ) (a., b. ) (a., b., c. ) (a., b. ) ( ) ( ) 2) 8. (a. tight junction, b. adherence junction, c. desmosome, d. hemidesmosome) ( ) ( ) ( ) 2) ( 108 ) 9. (a., b. ) Na + -Ca 2+ Na + ( ) Ca 2+ 1 (a., b. ) Na + (a., b. ) 44) (a., b. ) 14) 40
41 10. K (a., b. ) K (a., b. ) (a., b. ) (a., b. ) (a., b. ) (a., b. ) (a., b. ) (a., b. ) (a., b. ) ( ) (a., b. ) ( 108 ) 11. primitive reflexes 4 ( ) ( ) ( ) ( ) ( ) 25) 12. (a., b. ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) 1 ( ) ( ) ( ) (a., b. ) 3) ( ) 10) ( ) ( ) ( ) κ δ 12)
42 ( ) ( ) 16) 25. ( ) (a., b. ) (a., b. ) (a., b. ) (a., b., c., d. ) (a., b., c., d. ) 14) (a., b. ) (a., b. ) ( ) (a., b. ) TNM ( ) (a. I, b. II, c. III, d. IV) (a., b., c. ) TNM N > 0 (a., b. ) ( 108 ) ( ) (a., b., c. ) ( ) ( ) ( ) (a., b., c., d. ) ( ) 45)
43 Clostridium difficile ( ) 1, 46) ( ) ( ) ( 108 ) 36. (a., b. ) ( 108 ) 37. Courvoisier ( ) 7) 38. ( 108 a b ) ( ) ( ) 2) 41. (a. 1, b. 5, c. 10, d. 15) ( ) (a., b. X, c. ) ( ) 7) ( 108 ) 42. ( 108 e. )
44 44. ( ) ( ) (a., b. ) ( ) (a. 5, b. 15, c. 25) mg/dl 24 ( ) ( ) (a. 2, b. 2, c. 2 ) ( ) Erythroblastosis Fetalis ( ) ( ) ( ) ( ) 25) ( 108 ) 45. ( ) 7) ( ) ( ) ) ( 108 ) 46. ( ) ( ) (a., b., c. ) 5) CT ( ) PET ( ) (a., b., c. MRI, d. X, e. ) ( ) 44
45 (Amniotic Fluid Index; AFI) (a. 3, b. 5, c. 7, d. 9) cm (a, 14, b. 16, c. 18, d. 20) cm (a., b. ) ( ) 1 2 (a. 1-2, b. 5-25, c ) bpm ( ) 32 (a. 5, b. 15, c. 25) bpm (a. 30, b. 15 2, c. 1 ) (a., c. ) (a, b., c. ) (a. 5, b., 15, c. 25) bpm (a. 5, b. 15, c. 25) bpm 15 (a. 30, b. 1, c. 2 ) (a., b., c. ) (a., b., c. ) ( ) ( ) 9) 54. (a. 0.3, b. 0.8, c. 3, d. 8) % 9) ( 108 c. )
46 3.8 H 1. ( ) 45) ( ) (a., b., c., d. ) (a., b. ) 19) asterixis ( ) wing beating ( ) 17) 14. ( 108 b )
47 ( 108 ) 27. ( 108 ) 28. ( 108 b ) (a., b. ) (a., b. ) ( a 32 )
48 ( d ) ( e ) ( 108 Libman-Sacks (Systemic Lupus Erythematosus; SLE) 48
49 3.9 I ( 108 ) (a., b., c., d. ) (a., b. ) (a., b. ) 7) 7. ( 108 ) (a., b., c., d. ) (a., b. ) (a., b., c. ) (a., b. ) (a., b., c., d. ) (a., b., c. ) (a., b. ) (a., b. ) ( 108 a. ) 11. Selective Estrogen Receptor Modulator (SERM) ( ) ( ) ( ) 10) 12. ( 108 ) 49
50 (a , b. 0.15, c. 1.5, d. 15) 15) Waterhouse-Friderichsen syndrome ( ) ( ) ( ) 5) 16. botulinum toxin ( ) ( ) (a., b. ) (a., b. ) (a., b. ) tetanospasmin ( ) (a., b. ) (a., b. ) (a., b. ) (a., b. ) 1) 17. ( ) ( ) ( ) ( ) 47) ( 108 ) 11) 18. recruitment ( ) ( ) ( ) ( 108 PQ I I II II ) ( 108 ) 23. ( ) ( ) 50
51 ( ) ( ) ( ) ( ) Blumberg (a., b. ) (a., b., c. ) 48) 24. (Anti-Neutrophil Cytoplasmic Antibody; ANCA) (a. p-anca, b. c-anca, c. q-anca) (a. p-anca, b. c-anca, c. q-anca) (a. PR3, b. MPO) (a. PR3, b. MPO) MPO ( ) (a., b., c. ) MPO MPO ( ) 26) ANCA IgG (a., b. ) 6) ( ) (a., b. ) (a., b. ) 5) ( 108 ) 25. ( 108 ) ( 108 e. ) (a. SSRI, b. SNRI, c., d. ) ( ) ( ) (a., b., c., d. ) ( ) ( ) ( ) 10)
52 32. ( ) (a., b., c. ) ( ) ( ) ( ) (a., b. ) (a., b., c., d. ) (a. TNF-α, b. TGB-β, c. IL-6, d. IFN-α) 22) (a., b., c., d. ) ( 5, p.145) ) 33. ( 108 ) 34. ( ) 9) ( 108 ) ( 108 ) ( 108 ) (a. BCG, b., c. ), (a., b., c. ), (a., b., c. ), (a., b., c. ) 1) 41. ( 108 ) ( ) 1) ph (a., b. ) (a., b. ) (a., b., c. ) (a., b., c. ) 7)
53 ( 108 IgE ) ( 108 ) ( 108 ) 50. ( 108 ) ( ) ( ) (a., b. ) (a., b., c. ) (a., b., c., d., e. ) 80 % (a. 9, b. 18, c. 9, d. 18 ) 7) C ( ) ( ) (a., b. ) (a. 50 %, b. 30 %, c. ) ( ) 25) 55. ( 108 )
54 57. ( ) ( ) (a., b., c. ) CT (a., b., c. ) ( ) ( ) CT ( ) (a., b. ) 49) ( ) ( ) ( ) ( ) (a., b. ) (a., b. ) 26) ( 108 ) 58. ( 108 ) 59. ( 108 ) (a., b., c. ) ( ) (a., b., c. ) (a., b. ) ( 108 ) 62. ( 108 ) ( 108 )
55 ( 108 ) 68. prostatic hyperplasia hypertrophy hyperplasia 9 Harrison s Principles of Internal Medicine 19th Ed. (a., b. ) ( ) ( ) (a., b. ) PSA (a., b. ) (a., b. ) 15) ( ) ( ) ( ) ( ) ( ) ( ) (a., b., c. ) 7) ( ) ( ) NSAID (a., b. ) ( ) ( ) ( ) 31) 73. ( ) ( ) ( ) 10) ( 108 )
56 ( 108 ) ( ) ( ) 51) AFP hcg ( ) ( ) AFP ( ) hcg ( ) 23) 5 80 % 50) AFP ( ) BEP ( ) ( ) ( ) ( ) 56
57 4 4.1 A 1., 2., 3., 4., T,, 5.,,,,,, 6.,,,, 7.,, ACTH Cushing,,,,,, α, 8.,,,, 11) 9.,,, 10.,,,,, 11.,,,, 12.,,,,,,, 13.,,,,,,,,, 14.,,, 15., 57
58 16.,,,,,,, 17.,,,,,,,,,,,,,,,,,, 18.,,,,,,,,, 19.,,,,,,,, MAO, 108 L- L- 20.,,,,,,,,, 21.,,,,,,,,,,, 22.,,,,,,,, 23.,,, 24.,, 25. P AO2, P ao2, A a D O2,, Sp O2,,,, 26.,,,,
59 30.,,,,,, 31., Y,,,,,,,,,,,,, X, Duchenne, Becker ,,,, 35.,,,,,,, ,,,,,,,,,, 38.,,,, SPECT,,,, SPECT, ,, β,,,, β,, TGF-β 44.,,, 47.,,,,,,, PET 50.,,,, /, 100, SLE,,,,, SLE, Scl-70, 51.,,, Rickettsia, 59
60 52.,,,,,,, ST,, 54.,,,,, ACE, β,,,,, β,, ACE, β 55., CD19, CD20,,,,,, 1, 10,,, BCR-ABL,,,,,,,, 56.,, 57.,,, 58. T /, T, CD4,,, Ca,
61 4.2 B , ,, 6., %, 10.,,, 8-13, α,,,, Rapid Eye Movement,, 11. IgA,, 12.,, 13.,,,, LMP, EB,, 17. Protein Induced by Vitamin K Absence II, K,, K, II,,, K,,,, 21., 4 22.,,,,,,,,,,,, 23.,,,,, 25.,,,, 26.,,,,,,,,,,,,, 35.,,,,,,, 36.,,,,,,, Na + -Ca 2+, 61
62 ,, 38.,,,,,,,,,,,, 41.,,, 6, ,, 24, 30,,, 18, 6 44.,, 45.,, 48.,,,, III, , 1.030,, 3-4,,, MRI,, ,, ,,,,, 59.,,,, Wernicke, B 1,,,,,,,,,,, 60., M,, CMAP,,,,,,,,,,,, α 61.,,,, 62
63 4.3 C 2.,, 4.,,, 5.,, 7.,,,, 8. 9.,, 10.,, 11.,,,,,, 63
64 4.4 D 2. RB,, 80,,,, 4., ,,, S1,, S4 6.,,,,,,,, T,,,,, GABA,, GABA,, GABA 7. X,,,, X 8.,,,, 12. IgH,, IgH, BCL2,, 15.,,,,,,, 16.,,,,,, 17., ACTH,,,, 11-, 21., , rebound tenderness,,,,, 64
65 28.,,,, 29.,,,,, 30. (HTT),,,,,, X,,,,,,,,, Duchenne Becker in frame,, 15, Duchenne, 31.,,, 5-10,,,, 34. A16, 71,,,,,, 36.,, 37., Stevens-Johnson, 10 %, 30 %,,,, T,,,, 38., VEGF 44., 45.,,, 58. II,,,,,, A, D,,, 65
66 4.5 E 2., 30, 3.,, 6.,, 21, 17-, 9.,, I,, I,,,,,,, 11.,,,, 6-10 % 13.,,, 24-48, Behçet,,,, 14.,, 3-8, 8-15, WHO,,, 22.,,,,, 24.,, 29.,,,,,,,,,,,, 33., B 12,, dtmp, dump,,, (RDW),,, 35.,,,,, 37.,,,,,,,,,, 66
67 40., 41., 42.,,,,,,, 43., 37, 42,,, 4000 g,,,,,, 30, 15,,, TNM, M > 0, M = 0 N > 0 54.,,,, 55.,,, P=S,,,,,, 2-PAM (pralidoxime),,,, 56., FSH, ,,, II,,
68 4.6 F 7.,,,, D,, 9.,,,, 14.,,,, 20. 4, 5, 6, 3, 3, 4 22., ,,, β,,, 68
69 4.7 G 3., 7., 5,, 3-4,,,,,,, 5, 3 8. desmosome,,, 9., 3,,, 10.,,,,,,,,,, 11., 7-8, 2-3, 5-6, , 4, 8, 12, 32, 8, 4, 8, 20,,,,, 18. µ,,, 24. depersonalisation, 25.,,,,, 27.,,,, M > 0, IV,, 30.,,,, 18,, 35.,, Koplik, 41. 5,, X, 44.,,, 24, 15,,, 2,, 69
70 ,,, RDW 45.,, ,, 48., CT 53.,, 5, 18,,, 5-25,, 15, 15 2,,, 15, 15, 2,,,,
71 4.8 H 1., 8., 13., Wilson , 71
72 4.9 I 6.,, 10.,,,,,,, 11.,, ,, 16.,,,,,,,,, 17. 1,,, 18., 23.,,,,,,, 24. c-anca, p-anca, PR3, MPO,,, Fc,,,, 30., SSRI,,,,, 32.,, JAK2,, dry tap,,, TGF-β,, -II BCG,,, 43.,,,, 52. JC,,,,, 9 54.,,, 30 %, 72
73 57.,,,,,,,, KL-6, SP-A, SP-D, II,, 61.,,, 68., PSA,,,,, α 1, 5α-,, 72.,,, Sjögren,,,, TNF-α, IL Toll-like receptor,, 80.,,,,,,,,, 73
74 1),., 12. : ; )., 2. : ; ),., 7. : ; )., 3. : ; ) Kumar V, Abbas AK, Aster JC. Robbins and Cotran Pathologic Basis of Disease, 9th Ed. Philadelphia: Elsevier; ) Rosai J. Rosai and Ackerman s Surgical Pathology, 10th Ed. Elsevier; ),,., 2. : ; )., 10. : ; ),., 4. : ; ) Golan DE, Tashjian AH, Armstrong EJ, et al. ed. Principles of Pharmacology, 3rd Ed. Philadelphia: Lippincott Wiliams & Wilkins; )., 11. : ; ),, TEXT, 4. : ; ),. TEXT, 3. : ; ),., 3. : MEDSi; ) Kasper DL, Fauci AS, Hauser SL, et al. ed. Harrison s Principles of Internal Medicine, 19th Ed. Mc Graw Hill Education; ),,., 6. : ; )., 2. : ; ),., 5. : ; ),,,,.. : ; )., 10. : ; ).. : MEDSi; )., 2. : ; ),., 9. : ; ),., 3. : MEDSi; ) Kliegman RM, Stanton BF, St Geme III JW, et al. ed. Nelson Textbook of Pediatrics, 20th Ed. Philadelphia: Elsevier; ),,., : ; ),.. : ; ),., 4. : ; ),,., 4. : ; ),,., 3. : ; ),,., 12. : ; ),,., 34. : ; ),., 19. : ; ) Mills SE. Histology for Pathologists, 4th Ed. Philadelphia: Lippincott Williams & Wilkins;
75 35),,.. : ; ).. : ; ) Fazel R, Froelich JB, Williams DM, et al, A Sinister Development, N Engl J Med 2007; 357: ) Yanoff M, Sassani JW. Ocular Pathology, 7th Ed. Mosby Elsevier; ).. : ; ),., 5. : ; ) UICC TNM. TNM, 7. : ; )., 4. : ; ), jp/detail2?id=50093 ( ). 44).. ( ). 45),., : ; )., 3. : ; ),. NEW. : ; ),,., 13. : ; ),. CT, 3. : MEDSi; )., : ; ),., 3. : ;
2005 8) Robbins and Cotran Pathologic Basis of Disease (7th ed.) Kumar V, Abbas AK, Fausto N (eds.), W.B. Saunders, ) Rubin s Pathology (4 th ed
23344 mfukayama-tky@umin.ac.jp http://pathol.umin.ac.jp/ 19 50 2 / 19 50 3 / http://pathol/umin.ac.jp 1) Basic Pathology (7 th edition): Kumar V, Cotran RS, Robbins SL (eds.), W.B. Saunders, 2002 2) Essential
Microsoft Word - 平成24年度医学部卒業試験問題-2.docx
24 2012.10.25 13:00 15 00 5 2 10 20 60 80 110 10 1 6 7 /kg 1 12 20 30:2 AED 3 1 2 119 2 2 2 X X SpO 90% 60mmHg Primary Survey FAST CT 90% 100mmHg FAST 1 2L FAST(Focused assessment with sonography for trauma)
第 14 回血管病理研究会 日時 : 平成 20 年 10 月 10 日 ( 土 ) 会場 : 佐賀大学医学部臨床大講堂 3208 号室会長 : 徳永藏 ( 佐賀大学医学部病因病態科学講座 ) CRP MPO-ANCA 125IU/l CT mpa
第 4 回血管病理研究会 日時 : 平成 20 年 0 月 0 日 ( 土 ) 会場 : 佐賀大学医学部臨床大講堂 3208 号室会長 : 徳永藏 ( 佐賀大学医学部病因病態科学講座 ). 67 2008 CRP MPO-ANCA 25IU/l 009 2 CT mpa GCA PSL 50 mg CRP MPO-ANCA mpa GCA 4 mpa ovarlap 2 TLR 2 2. 対象 方法
3 6 6 8 5 5 0 4 3 4 4 0,000 3 ID ID ID 4 7 9 :5 4 5 60-8048 NACOS TEL: 075-45-366 FAX: 075-45-366 E-mail: jiao@nacos.com 3. Power Point PC 0 5. Power Point PC 7 3 3. 3 5 PC PC PC Windows Power Point USB
日本呼吸器学会雑誌第48巻第6号
Fig.1 Cutaneousfindingsandpathologicalfindingsofatransbronchiallungbiopsy(TBLB)andlichenifiedeczemaoftherightforearm.Thepatienthadlichenifiedeczemaonhisextremitiesandbodytrunk (1a:rightforearm,1b:leftthigh).Therewasinfiltrationoftheinflammatorylymphocytes,edemaandabrasioninthetype2alveolarepithelium
国試過去問集.PDF
I 89 16 3 130 ab c AMPcAMP a 1 --- b c --- 2 --- --- 3 --- --- 4 --- --- 5 --- --- camp camp Ca 2+ β1 camp A camp camp A β1 p.156 β p.146 b. p.157 p135 (ANP) p157 c PDE-III p.157 p.157, 183 PDE C Ca PDE-III
20－121
20 121 150 1 20 121 1 HbA1C 1 2 2 HbA1C 3 2 4 5 HbA1C 1 HbA1C -NH2 -CHO HbA1C 1 1 HbA1C HbA1C HbA1C HbA1C HbA1C 120 HbA1C HbA1C 1 2 2 HbA1C 120 10 10 10 3 β β 1 1 GAD ICA 2 4 HbA1C 2 1 2 5 2 20 121 150
A(6, 13) B(1, 1) 65 y C 2 A(2, 1) B( 3, 2) C 66 x + 2y 1 = 0 2 A(1, 1) B(3, 0) P 67 3 A(3, 3) B(1, 2) C(4, 0) (1) ABC G (2) 3 A B C P 6
1 1 1.1 64 A6, 1) B1, 1) 65 C A, 1) B, ) C 66 + 1 = 0 A1, 1) B, 0) P 67 A, ) B1, ) C4, 0) 1) ABC G ) A B C P 64 A 1, 1) B, ) AB AB = 1) + 1) A 1, 1) 1 B, ) 1 65 66 65 C0, k) 66 1 p, p) 1 1 A B AB A 67
橡皮膚科資料
85-3 Langerhans 650 750/mm 3 B cell 82-71 tonofibril 64-23 1500/mm 2 2 80-71 neural crest Stage1 4 76-21 Langerhans high-level clear cell Birbeck granule Langerhans Langerhans intercellular bridge 76-22
23 1 Section ( ) ( ) ( 46 ) , 238( 235,238 U) 232( 232 Th) 40( 40 K, % ) (Rn) (Ra). 7( 7 Be) 14( 14 C) 22( 22 Na) (1 ) (2 ) 1 µ 2 4
23 1 Section 1.1 1 ( ) ( ) ( 46 ) 2 3 235, 238( 235,238 U) 232( 232 Th) 40( 40 K, 0.0118% ) (Rn) (Ra). 7( 7 Be) 14( 14 C) 22( 22 Na) (1 ) (2 ) 1 µ 2 4 2 ( )2 4( 4 He) 12 3 16 12 56( 56 Fe) 4 56( 56 Ni)
Behçet 病，サルコイドーシス，再発性多発軟骨炎―診断と鑑別を中心にー
58 5 260 270 2015 Behçet Behçet 58 4 Sjögren IgG4 5 Behçet Behçet Behçet 1937 Hulusi Behçet 4 1 25 19,147 HLA B51 A26 2 HLA B51 4 1 Behçet Behçet Behçet Behçet 2 3 Recurrent Aphthous Stomatitis RAS 26
第86回日本感染症学会総会学術集会後抄録（I）
κ κ κ κ κ κ μ μ β β β γ α α β β γ α β α α α γ α β β γ μ β β μ μ α ββ β β β β β β β β β β β β β β β β β β γ β μ μ μ μμ μ μ μ μ β β μ μ μ μ μ μ μ μ μ μ μ μ μ μ β
5 CSF 6 CSF 7 CSF CSF CDV CDV GFAP CSF Pandy test NSE MBP LDH mu/ml 0-5 /µl AST mu/ml CK mu/ml <25 mg/dl<45 mg/dl GLU
CT MRI CSFCSF CSF CSF CSF CSF CSF (cisternal puncture) CSF 20-23G 90 (20-23G) : CSF
1.2 M N M d- BBB / ChE etc ChE etc CCh BCh etc Ach ChE 2 Ach ChE PAM ChE
1 - d- etc etc d-tc ChE > < < < > > > or 1.1 1 d- < dtc Na + Na + I II ChE ChE ChE ( ) T Ca++ 1 Na + K + Na + Ach Ach Ach BTX Mg 2+ Ach CAT TTX Ach 1.2 M N M d- BBB / ChE etc ChE etc CCh BCh etc Ach ChE
…GŒÆ›u››‘KŒâ‚è_cs1.indd
1 1-1 4 1-2 a. b. c. d. e. 1-3 A. 4 B. 3 1-4 a. b. c. d. e. 1-5 1-6 4 1-7 a. b. c. d. e. 1-8 a. b. c. d. e. 1-9 1-10 A. 2 B. C. 1-11 a. / 2 b. / c. / d. / e. / 1-12 a. T b. c. M d. e. 1-13 1-14 1-15 16
051
Aug. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 4 389( 15 ) 1. MDS collagenase 2. 1 3. 4. / 390( 16 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 4 Aug. 4 4 2004 10 2 1 NTT Aug. THE JAPANESE JOURNAL OF ANTIBIOTICS
1) a) b) CRP c) d) e) a,b b,c c,d d,e a,e b,d 2) CKD a) ACE ARB b) 2mg/dL ACE ARB c) 2mg/dL d) e) ACE ARB a,b b,c c,d d,e a,e b,d 3) a) 130/85mmHg b)
2010.1.13 1) 4) 2 18 1) 1 2 3 4 2) 1 2 85 3 3) 1 metabolizer 2 metabolizer 3 metabolizer 4 metabolizer 4) CYP 1 2 metabolizer 3 metabolizer 4 5 6 4 7 2 5 (PPI) 1 2 PPI 2 3 2 3 3 3 3 PPI 3 1 ph 4 5 1) 5)
のコピー
70 2001x 9 20 26 27 1 1 2 132/83mmHg 79/ 36.0 1 WBC 6900/mm 3 RBC 432x10 3 /mm 3 Hb 11.8g/dl Hct 39.1 MCV MCH MCHC 90.5fl 27.3pg 30.2g/dl Plt 299x10 3 /mm 3 granulocyte 38% 201x 9 27 S S 2 3 PAS
untitled
Ref. No: KiG14B23-Kokushi22-R01 22 1/23 Ans Ans 1 75 64 74 8 75 75 Ans 9 75.1 2010 Ans Ans 1000 Ans 85cm 90cm 25 130mmHg 85mmHg 100mg/dl HbA1c 5.6 HDL 150mg/dl HDL-C 40mg/dl 1 3 Ans 1 (): 2 (): 3 (): 4
Microsoft Word - 三重大学版PBLマニュアル.doc
Problem-based Learning PBL * 1 * 2 * 1 Problem-based Learning Project-based Learning * 2 1 15 2 reflection self-directed learning (PBL-tutorial) (Task-based Learning, Project-based Learning) 11 3 4 (Theoretical
ｎｓｇ０２－１３／ｋｙ０４５０５９３０１６０００３３２１０
φ φ φ φ κ κ α α μ μ α α μ χ et al Neurosci. Res. Trpv J Physiol μ μ α α α β in vivo β β β β β β β β in vitro β γ μ δ μδ δ δ α θ α θ α In Biomechanics at Micro- and Nanoscale Levels, Volume I W W v W
_0212_68<5A66><4EBA><79D1>_<6821><4E86><FF08><30C8><30F3><30DC><306A><3057><FF09>.pdf
中高齢者の健康・いきいきライフスタイルづくり調査
1 -- -- 10 11 12 1998-2000 Exercise: A Guide from the National Institute on Aging 1 61-80 26 T PHA Streptoccocal enterotoxin ASEA (IL-2; Th1 ) IL-4Th2 IgE T T - Bcl-2 Fas T PHA SEA IL2 T PHA SEA IL2
37, 9-14, 2017 : cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin CD 7 Clostridium difficile CD CD associate
37, 9-14, 2017 : 36 2015 8 6 cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin 20 1983 2016 3 CD 7 Clostridium difficile CD CD associated diarrhea : CDAD CD 1,2 PPI 3 1 36 33 2015 8 6 5 5
研修コーナー
l l l l l l l l l l l α α β l µ l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
取扱説明書 ［F-12C］
F-12C 11.7 1 2 3 4 5 6 7 8 9 10 11 12 13 14 a bc b c d d a 15 a b cd e a b c d e 16 17 18 de a b 19 c d 20 a b a b c a d e k l m e b c d f g h i j p q r c d e f g h i j n o s 21 k l m n o p q r s a X
REM Rapid Eye Movement REM Zzz Non-REM
Sleep and sleep-related disorders in the elderly 20051027 REM Rapid Eye Movement REM Zzz Non-REM 90 180 270 360 90 How old is the elderly in sleep? 40 In: Primer of Polysomnography Circadian rhythm 24
さくらの個別指導 ( さくら教育研究所 ) A 2 2 Q ABC 2 1 BC AB, AC AB, BC AC 1 B BC AB = QR PQ = 1 2 AC AB = PR 3 PQ = 2 BC AC = QR PR = 1
... 0 60 Q,, = QR PQ = = PR PQ = = QR PR = P 0 0 R 5 6 θ r xy r y y r, x r, y x θ x θ θ (sine) (cosine) (tangent) sin θ, cos θ, tan θ. θ sin θ = = 5 cos θ = = 4 5 tan θ = = 4 θ 5 4 sin θ = y r cos θ =
1 Stevens-Johnson syndromesjs toxic epidermal necrolysisten SJSTEN No No SJS
Drug Information News http://www.mhlw.go.jp/houdou/2004/07/h0729-1.html 1 Stevens-Johnson syndromesjs toxic epidermal necrolysisten SJSTEN No.163 12 11 No.177 14 5 9 12 SJSTEN No.163No.177 2 SJS erythema
BUN, CRP K mg/ cm, 49.6 kg, BMI /72 mmhg, 92/ Hb 6.7 g/dl PT-INR CT 1 MRI 2a, b T1 T2 T1 MRI
20 2 2015 1 2 3 85 K CT Abstract A case of renal subcapsular hematoma resulting from trigger point injection under excessive effect of anticoagulant YAMANE Tateki, UMEDA Akira and SHIMAO Hitoshi An 85-year-old
第１４〜１５回 Ｔ細胞を介する免疫系.pptx
MBL CD8 CD4 8.1 8.2 5.20 8.3 8.4 8.5 8.6 8.7 8.8 8.9 8.10 8.18 B7 CD28 CD28 B7 CD28 8.13 2.22 NK Toll(TLR) LBP! LPS dsrna ssrna TLR1/2/6! TLR4 TLR5 TLR3 TLR7/9 CD14! JNK/p38! MyD88! IRAK! TRAF! NFκB! TNF-α
マニュアル第４版表紙PDF
5 2004 4 1 5 2004 1968 1993 1994 1996 1998 2001 2004 3 I 1 1 2 2 3 12 4 24 5 48 6 59 7 65 8. 68 9 72 10 76 11 80 12 82 13 84 14 88 15 98 16. 106 17. (AIDS) 108 18 113 19 117 20 119 21 TPN 122 22 125 23.
44 4 I (1) ( ) (10 15 ) ( 17 ) ( 3 1 ) (2)
(1) I 44 II 45 III 47 IV 52 44 4 I (1) ( ) 1945 8 9 (10 15 ) ( 17 ) ( 3 1 ) (2) 45 II 1 (3) 511 ( 451 1 ) ( ) 365 1 2 512 1 2 365 1 2 363 2 ( ) 3 ( ) ( 451 2 ( 314 1 ) ( 339 1 4 ) 337 2 3 ) 363 (4) 46
i ii i iii iv 1 3 3 10 14 17 17 18 22 23 28 29 31 36 37 39 40 43 48 59 70 75 75 77 90 95 102 107 109 110 118 125 128 130 132 134 48 43 43 51 52 61 61 64 62 124 70 58 3 10 17 29 78 82 85 102 95 109 iii
臨床神経45-1.indb
59 Case of the Issue No. 9 carpal tunnel syndrome: CTS CTS CTS CTS nerve conduction study; NCS needle electromyography; nemg NCS carpal tunnel syndrome: CTS 1 CTS 4 CTS 45 65 1 3 2 CTS CTS 1999 American
S I. dy fx x fx y fx + C 3 C dy fx 4 x, y dy v C xt y C v e kt k > xt yt gt [ v dt dt v e kt xt v e kt + C k x v + C C k xt v k 3 r r + dr e kt S dt d
S I.. http://ayapin.film.s.dendai.ac.jp/~matuda /TeX/lecture.html PDF PS.................................... 3.3.................... 9.4................5.............. 3 5. Laplace................. 5....
日本呼吸器学会雑誌第44巻第10号
β Table1 Laboratoryfindingsonthefirstvisit Hematology WBC Neut. Lyn. Mon. Eos. Bas. RBC Hb Ht Plate 5,650 /μl 79.2 % 14.9 % 3.9 % 1.8 % 0.2 % 418 10 4 /μl 12.5g/dl 38.4 % 21.2 10 4 /μl Serology CRP IgG
Gauss Gauss ɛ 0 E ds = Q (1) xy σ (x, y, z) (2) a ρ(x, y, z) = x 2 + y 2 (r, θ, φ) (1) xy A Gauss ɛ 0 E ds = ɛ 0 EA Q = ρa ɛ 0 EA = ρea E = (ρ/ɛ 0 )e
7 -a 7 -a February 4, 2007 1. 2. 3. 4. 1. 2. 3. 1 Gauss Gauss ɛ 0 E ds = Q (1) xy σ (x, y, z) (2) a ρ(x, y, z) = x 2 + y 2 (r, θ, φ) (1) xy A Gauss ɛ 0 E ds = ɛ 0 EA Q = ρa ɛ 0 EA = ρea E = (ρ/ɛ 0 )e z
64 3 g=9.85 m/s 2 g=9.791 m/s 2 36, km ( ) 1 () 2 () m/s : : a) b) kg/m kg/m k
63 3 Section 3.1 g 3.1 3.1: : 64 3 g=9.85 m/s 2 g=9.791 m/s 2 36, km ( ) 1 () 2 () 3 9.8 m/s 2 3.2 3.2: : a) b) 5 15 4 1 1. 1 3 14. 1 3 kg/m 3 2 3.3 1 3 5.8 1 3 kg/m 3 3 2.65 1 3 kg/m 3 4 6 m 3.1. 65 5
加藤茂孝先生
Shigetaka KATOW 2009 4 24 WHO 5 9 1 5 16 1 TV 6 12 6 11 WHO 6 4 5 12 E-mail : modern_media@eiken.co.jp 2009. 4. 28. http:idsc.nih.go.jpidwrkanjaweeklygraph01flu.html 0101-0051 - RIKEN Center of Research
2 W.T T.S. 70 2 1 238 WBC7400/µl, RBC 386 10 4 /µl, Hb 11.6 g/dl, Ht 36.2%, PLT 25 10 4 /µl AST 19 IU/l, ALT 11 IU/l, LDH 182 IU/l, BUN 15 mg/dl, Cr 0.54 mg/dl, CRP6.83 mg/dl, RF 353.9IU/ml, CCP 28.0IU/ml
日歯雑誌（Ｈ２８・８月号）別刷り／ポスターセッション とびら
α P. gingivalis P. gingivalis αsmatgf- VEGF-A α in vitro μ Porphyromonas gingivalis in vitro Porphyromonas gingivalis β β β JBiolChem. μ μ μ β Porphyromonas gingivalis in vitro μ α β α
/12/28 UP 3+, TP 4.2g/dl, Alb 1.9g/dl PSL 50mg/day 1/17 PSL 45mg/day PSL 2006/4/4 PSL 30mg/day mpsl mpsl1000mg 3 2 5/ :90 / :114/64 mmhg
17 2005/12/28 UP 3+, TP 4.2g/dl, Alb 1.9g/dl PSL 50mg/day 1/17 PSL 45mg/day PSL 2006/4/4 PSL 30mg/day mpsl mpsl1000mg 32 5/8 36.1 :90 /:114/64 mmhg 166.2 cm64.3 kg 3.9 g/dl 1.6 g/dl 382 mg/dl 408 mg/dl
AD 2004/8/22 1. 30 90 mmhg 2. 3 100 refilling COPD etc. etc. PCPS IVR Helical CT DSA IVR DVT US/CT Scintigaraphy Ventilation / Perfusion VP scans High probability R DSA Gold standard MSCT
顔面神経麻痺を来したMPO―ANCA 陽性の中耳炎２症例
11367 : MPOANCA MPO ANCA MPOANCA 134EU MPO ANCA 67EU MPOANCA ANCA : MPOANCAANCA antineutrophil cytoplasmic antibody ; ANCA Davies IgG ANCA PR3proteinase3ANCA MPOmyeloperoxidaseANCA Wegener PR3ANCA MPO
indd
18 61 1 2011 症例報告 2010 5 13 2010 12 20 A Case of Varicella with Severe Back Pain in a Patient with Systemic Lupus Erythematosus RIE SAITO, KIORI YANO, FUMIKO KATSUSHIMA, HARUYO IWADATE, HIROKO KOBAYASHI,
A B 1.A B A B 2.A B A B 3.A
1 1. 2.WHO 3. 4. 5. 2 2.0mg/kg / 1. 2. 3. 4. 5. 3 1. 90 2. 3. 4. 5. 4 1. 2. 3. 4. 5. 1 21 5 1. 2. 2050 61 3. 1 4. 5. 6 1. ----------- 2. ---- 3. ------ 4. -------- 5. --------- 7 A B 1.A B------------------A
19 8 1970 20 10 4 1
19 8 1970 20 10 4 1 IgE 1960 % 1970 20%, 1990 40% 1998 70% 20 IgE 21 90% IgE IgE (%) 70 60 50 40 30 20 10 0 1970 1975 1980 1985 1990 1995 2000 2005 1. 2005 10 2 30 IgE 2. 3 1. B IgE T IgE IgE IgE 2 T IgE
名称未設定
[ ( 20120319-3.xml) ] [Class Name] [Super Classes] Any / / [Sub Classes (24)] IgG4 Seronegative Spondyloarthropathy(SNSA) Seronegative Spondyloarthropathy(SNSA)_2 [Description].. [ Page - 1 / 43 ] [ (
untitled
28 20 1 31 4 2 25 1 IgG IgA IgM IgE IgM 2 60 80 70 60 60 40 20 80 35 45 kg 150cc 100 120cc 100cc 30 40cc 7,000g 500cc 120cc 120 5=600cc 600g 30 2,100cc 1,000cc 3 4 14 5 6 7 8 9 10 11 12 SIDS SIDS SIDS
72 20 Ope / class Alb g/ cm 47.9kg : /min 112/60m
72 20Ope 68 69 2006 4 50 20 / 52 2006 4 1 2006 4 4 24 class 699.4 5 2 5 23 6 6 15 6 19 6 16 Alb2.03+ 7.5g/ 6 21 153.5cm 47.9kg : 36.7 89/min112/60mmHg (-) (-)S1 S2 S3(-) S4(-) - - 6 15 (+) TP4.9g/dl Alb2.0g/
Mast Cell Tumor : MCT c-kit MCT F F MCT C c-kit DNA Canine DNA Ver DNA c-kit C c 1275 A G F c.2355 G A DNA F C F C c-kit MCT c-kit DNA MCT Kiel T B kg cm T T Stage a UW25 P MDR1 B L T B L Leptospira L
総研大恒星進化概要.dvi
The Structure and Evolution of Stars I. Basic Equations. M r r =4πr2 ρ () P r = GM rρ. r 2 (2) r: M r : P and ρ: G: M r Lagrange r = M r 4πr 2 rho ( ) P = GM r M r 4πr. 4 (2 ) s(ρ, P ) s(ρ, P ) r L r T
Atlas_j060419
Hill s Atlas of Veterinary Clinical Anatomy 1 29 30 2 3 4 5 31 32 33 34 35 36 37 6 7 8 9 10 11 12 13 38 39 40 41 14 15 16 17 18 19 20 21 22 23 24 25 26 27 42 43 44 45 46 47 48 49 50 51 52 53 54 55 28 81
untitled
2303 16 2 9 1 14 5 31 (423) 1 (4), (6) C55H84ClN17O21S3 HCl (BLM-A2) 1487.47 11 2 1 4 104 2 14 5 31 [ ] ( ) ( ) 1. 15mg 30mg( ) 5 20mL 1 5mg( ) 2. 3 15mg 30mg( ) 5mL 1mg( ) 1mL 3. 5mg 15mg( ) 4. 1 2 1
近畿中国四国農業研究センター研究報告 第７号
230 C B A D E 50m 558 0 1km (mg L 1 ) T N NO 2 3 N NH 4 N 2.0 0 (a) 2001 1.5 6 20 21 5 1.0 0.5 0.0 2.0 1.5 1.0 0.5 0.0 14:00 17:00 (b) 2001 7 3 4 20:00 23:00 2:00 (h) 5:00 8:00 11:00 10 0 5 10 15
50mg 75mg (1) H 3 C O OH HO H O O H OH SO H 3 Na H H N H 2 N NH OH H N O O H H O OH H 3 C H O O N H H H HO H NH CH 3 HN HO H OH O H OH H NH
3240 14 8 8 50mg 75mg 13 6 25 1-(1) H 3 C O OH HO H O O H OH SO H 3 Na H H N H 2 N NH OH H N O O H H O OH H 3 C H O O N H H H HO H NH CH 3 HN HO H OH O H OH H NH O N O C 56 H 70 N 9 NaO 23 S 1292.26 5-[(1S,2S)-2-
cm H.11.3 P.13 2 3-106-
H11.3 H.11.3 P.4-105- cm H.11.3 P.13 2 3-106- 2 H.11.3 P.47 H.11.3 P.27 i vl1 vl2-107- 3 h vl l1 l2 1 2 0 ii H.11.3 P.49 2 iii i 2 vl1 vl2-108- H.11.3 P.50 ii 2 H.11.3 P.52 cm -109- H.11.3 P.44 S S H.11.3
免疫Ⅱ
100 100 100 1990 127 DNA DNA DNA DNA hybridization DNA RNA DNA DNA 128 12 µδγαε 129 300 1,200 500 50012 4 24,000 1,20024,000 2.910 7 10 8 rejection major histocompatibility complex MHC MHC MHC 130 MHC
(1.2) T D = 0 T = D = 30 kn 1.2 (1.4) 2F W = 0 F = W/2 = 300 kn/2 = 150 kn 1.3 (1.9) R = W 1 + W 2 = = 1100 N. (1.9) W 2 b W 1 a = 0
1 1 1.1 1.) T D = T = D = kn 1. 1.4) F W = F = W/ = kn/ = 15 kn 1. 1.9) R = W 1 + W = 6 + 5 = 11 N. 1.9) W b W 1 a = a = W /W 1 )b = 5/6) = 5 cm 1.4 AB AC P 1, P x, y x, y y x 1.4.) P sin 6 + P 1 sin 45
E3200 BV FOLFOX4 FOLFOX4 PFS % 0.42, 0.65 p< log-rank % FOLFOX4 8.6% FOLFOX % FOLFOX4 259/ % FOL
E3200 BV FOLFOX4 FOLFOX4 PFS 4.5 7.5 0.518 95% 0.42, 0.65 p
GL_尾崎班_D.indd
Circulation Journal Vol. 72, Suppl. IV, 2008 1319 Churg-Strauss ANCA ANCA 1 1 1320 Circulation Journal Vol. 72, Suppl. IV, 2008 ANCA 1 ANCA ANCA 2 Circulation Journal Vol. 72, Suppl. IV, 2008 1321 2 2
‰Łflç‘ÇŁ\”ƒ(’FŁª›ð)-A4
1 14163 1611 (2002) 32007 3 3 196 2 1416 ( ) Medsger modified Rodnan total skin thickness score EBM placebo control ACEEBM EBM 3 1611 4 5 (Systemic Sclerosis : SSc) 1980 (1) 1) 200310 (2) 2003 Scl-70 1
さくらの個別指導 ( さくら教育研究所 ) 1 φ = φ 1 : φ [ ] a [ ] 1 a : b a b b(a + b) b a 2 a 2 = b(a + b). b 2 ( a b ) 2 = a b a/b X 2 X 1 = 0 a/b > 0 2 a
![さくらの個別指導 ( さくら教育研究所 ) 1 φ = φ 1 : φ [ ] a [ ] 1 a : b a b b(a + b) b a 2 a 2 = b(a + b). b 2 ( a b ) 2 = a b a/b X 2 X 1 = 0 a/b > 0 2 a](/thumbs/97/131721994.jpg "さくらの個別指導 ( さくら教育研究所 ) 1 φ = φ 1 : φ [ ] a [ ] 1 a : b a b b(a + b) b a 2 a 2 = b(a + b). b 2 ( a b ) 2 = a b a/b X 2 X 1 = 0 a/b > 0 2 a")
φ + 5 2 φ : φ [ ] a [ ] a : b a b b(a + b) b a 2 a 2 b(a + b). b 2 ( a b ) 2 a b + a/b X 2 X 0 a/b > 0 2 a b + 5 2 φ φ : 2 5 5 [ ] [ ] x x x : x : x x : x x : x x 2 x 2 x 0 x ± 5 2 x x φ : φ 2 : φ ( )
(1) ) ) (2) (3) (4) (5) (1) (2) b (3)..
... -1... -1... -2... -6.... -1 (1)... -1 1)... -1 2)... -14 (2)... -19 (3)... -52 (4)... -18 (5)... -136.... -196 (1)... -196 (2) b... -224 (3)... -233.... -251.... -286.... -289 (1)... -289 (2)... -32
_02三浦.indd
36, 7-11, 2016 IPD PCV 5 3 80% 1 invasive pneumococcal disease ; IPD 2010 7 PCV7 2013 13 PCV13 IPD IPD 2,3 2015 1 2015 12 5 1 IPD 2015 1 12 IPD 5 IPD 1 4 2 5 http://pneumocatch.jp/ 5 Statens Serum Institut
( )
18 10 01 ( ) 1 2018 4 1.1 2018............................... 4 1.2 2018......................... 5 2 2017 7 2.1 2017............................... 7 2.2 2017......................... 8 3 2016 9 3.1 2016...............................
4. ϵ(ν, T ) = c 4 u(ν, T ) ϵ(ν, T ) T ν π4 Planck dx = 0 e x 1 15 U(T ) x 3 U(T ) = σt 4 Stefan-Boltzmann σ 2π5 k 4 15c 2 h 3 = W m 2 K 4 5.
A 1. Boltzmann Planck u(ν, T )dν = 8πh ν 3 c 3 kt 1 dν h 6.63 10 34 J s Planck k 1.38 10 23 J K 1 Boltzmann u(ν, T ) T ν e hν c = 3 10 8 m s 1 2. Planck λ = c/ν Rayleigh-Jeans u(ν, T )dν = 8πν2 kt dν c
Note.tex 2008/09/19( )
1 20 9 19 2 1 5 1.1........................ 5 1.2............................. 8 2 9 2.1............................. 9 2.2.............................. 10 3 13 3.1.............................. 13 3.2..................................
untitled
PGF 17 6 1 11 1 12 1 2 21 2 22 2 23 3 1 3 1 3 2 3 3 3 4 3 5 4 6 4 2 4 1 4 2 4 3 4 4 4 5 5 3 5 1 5 2 5 5 5 5 4 5 1 5 2 5 3 6 5 6 1 6 2 6 6 6 24 7 1 7 1 7 2 7 3 7 4 8 2 8 1 8 2 8 3 9 4 9 5 9 6 9 3 9 1 9
1. 2 P 2 (x, y) 2 x y (0, 0) R 2 = {(x, y) x, y R} x, y R P = (x, y) O = (0, 0) OP ( ) OP x x, y y ( ) x v = y ( ) x 2 1 v = P = (x, y) y ( x y ) 2 (x
. P (, (0, 0 R {(,, R}, R P (, O (0, 0 OP OP, v v P (, ( (, (, { R, R} v (, (, (,, z 3 w z R 3,, z R z n R n.,..., n R n n w, t w ( z z Ke Words:. A P 3 0 B P 0 a. A P b B P 3. A π/90 B a + b c π/ 3. +
医系の統計入門第 2 版 サンプルページ この本の定価 判型などは, 以下の URL からご覧いただけます. このサンプルページの内容は, 第 2 版 1 刷発行時のものです.
医系の統計入門第 2 版 サンプルページ この本の定価 判型などは, 以下の URL からご覧いただけます. http://www.morikita.co.jp/books/mid/009192 このサンプルページの内容は, 第 2 版 1 刷発行時のものです. i 2 t 1. 2. 3 2 3. 6 4. 7 5. n 2 ν 6. 2 7. 2003 ii 2 2013 10 iii 1987
006 11 8 0 3 1 5 1.1..................... 5 1......................... 6 1.3.................... 6 1.4.................. 8 1.5................... 8 1.6................... 10 1.6.1......................
第十四改正日本薬局方第二追補
461 3 3 3 5 5 6 6 10 18 19 79 81 101 113 127 133 139 145 147 152 153 156 158 165 3 19 20 21 22 22 23 24 25 26 26 27 28 29 29 30 31 dl 32 dl 33 34 34 36 36 37 38 38 38 39 40 42 42 42 43 44 45 46 46 47 48
4.4 R............................................. 13 4.5 q.............................................. 13 4.6 s....................................
2014.04.12 2014.12.12 1 3 2 4 2.1............................................ 4 2.2 Einthoven triangle........................................ 4 2.3............................................ 4 2.4.............................................
1 2 2 ANCA pouci immune IgG C3 ANCA 68 '01 '02 7 UN 14mg/dl, Cr 0.7 mg/dl, -, - ' UN 45mg/dl, Cr 2.4 mg/dl, Ht 29.5%, 4+, cm 61
1 2 2 ANCApouci immune IgG C3 ANCA 68 '01 '02 7 UN 14mg/dl, Cr 0.7 mg/dl, -, - '03 2 3 31 UN 45mg/dl, Cr 2.4 mg/dl, Ht 29.5%, 4+, 3+ 4 14 156.0 cm 61.5 kg 36.9 158/92 mmhg 90 1. ANCA 2. 3. IgG4 deposit
I II
I II I I 8 I I 5 I 5 9 I 6 6 I 7 7 I 8 87 I 9 96 I 7 I 8 I 9 I 7 I 95 I 5 I 6 II 7 6 II 8 II 9 59 II 67 II 76 II II 9 II 8 II 5 8 II 6 58 II 7 6 II 8 8 I.., < b, b, c, k, m. k + m + c + c b + k + m log
(1) θ a = 5(cm) θ c = 4(cm) b = 3(cm) (2) ABC A A BC AD 10cm BC B D C 99 (1) A B 10m O AOB 37 sin 37 = cos 37 = tan 37
4. 98 () θ a = 5(cm) θ c = 4(cm) b = (cm) () D 0cm 0 60 D 99 () 0m O O 7 sin 7 = 0.60 cos 7 = 0.799 tan 7 = 0.754 () xkm km R km 00 () θ cos θ = sin θ = () θ sin θ = 4 tan θ = () 0 < x < 90 tan x = 4 sin
v v = v 1 v 2 v 3 (1) R = (R ij ) (2) R (R 1 ) ij = R ji (3) 3 R ij R ik = δ jk (4) i=1 δ ij Kronecker δ ij = { 1 (i = j) 0 (i
1. 1 1.1 1.1.1 1.1.1.1 v v = v 1 v 2 v 3 (1) R = (R ij ) (2) R (R 1 ) ij = R ji (3) R ij R ik = δ jk (4) δ ij Kronecker δ ij = { 1 (i = j) 0 (i j) (5) 1 1.1. v1.1 2011/04/10 1. 1 2 v i = R ij v j (6) [
2010 年 6 月 25 表 身体所見 134 cm 31 kg /60 mmhg 83/ ,
24 シンポジウム Ⅲ 要旨 NPPV NPPV 緒 IPF 4 5 1 IPF 2004 2 QOL 179 10 現 10 18 2008 10 言 状 3.4 8.3 76.2 41 37.2 13.6 3 1 症 例 呈 示症例 患者 61 主訴 既往歴 30 45 家族歴 喫煙歴 飲酒歴 職歴 現病歴 13 NSIP 15 1 HOT 15 7 2010 年 6 月 25 表 1 1998
(2009) 1... / 1 ( ) / 1 ( ) / 1 ( ), 2 ( )
212009................................................ 2............................................ 115 (2009) 1... / 1 ( )........................................... 4 2... / 1 ( )......................................
9 10 21 4 23 3 24 11 2012 24 5 28 4
9 10 21 4 23 3 24 11 2012 24 5 28 4 1 2 3 4 5 6 7 8 9 1 2 3 4 10 11 12 13 14 15 16 SIDS 17 18 19 20 21 22 1 2 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 1 2 3 4 5 6 01 3 4 P1 P P 10 11
高脂血症の検査
35 30 Buffy coatbuffy coat EDTA Na Na Ca RBC Hb Ht WBC Plt ESR TP Alb CRP GOTGPTLDH BUN Cre UA HbA1C TC TG NaKClCaPFe B12 36 RBC 410530 /μl 380480 /μl Hb 13.517.6g/dL 11.315.2g/dL Ht 3648% 3443% MCV MCH